Oncology

FDA approves first-in-class treatment for low-risk MDS with transfusion-dependent anemia

The US Food and Drug Administration (FDA) approved imetelstat for adults with low- to intermediate-1-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia who require 4 of more red blood cell units over 8 weeks and have not responded to, lost response to, or ineligible for erythropoiesis-stimulating agents. The approval of the...